BiotechTube

Azacitidine + Venetoclax

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndromes (MDS)

Conditions

Myelodysplastic Syndromes (MDS)

Trial Timeline

Jan 12, 2017 → Jan 1, 2027

NCT ID
NCT02942290

About Azacitidine + Venetoclax

Azacitidine + Venetoclax is a phase 1 stage product being developed by AbbVie for Myelodysplastic Syndromes (MDS). The current trial status is active. This product is registered under clinical trial identifier NCT02942290. Target conditions include Myelodysplastic Syndromes (MDS).

What happened to similar drugs?

7 of 19 similar drugs in Myelodysplastic Syndromes (MDS) were approved

Approved (7) Terminated (7) Active (7)
✅decitabine + azacitidineEisaiApproved
✅DeferasiroxNovartisApproved
✅ICL670/DeferasiroxNovartisApproved
✅deferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical
6
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03573024Phase 2Active
NCT02942290Phase 1Active

Competing Products

20 competing products in Myelodysplastic Syndromes (MDS)

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
23
JSP191Jasper TherapeuticsPhase 1
11
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Erlotinib HydrochlorideAstellas PharmaPhase 2
35
Decitabine + Decitabine + DecitabineEisaiPhase 2
35
Decitabine + Valproic AcidEisaiPhase 2
35
decitabine + decitabineEisaiPhase 2
35
decitabine + azacitidineEisaiApproved
35
DecitabineEisaiPhase 2
27
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
29
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
35
Subcutaneous DecitabineEisaiPhase 1
21
DecitabineEisaiPhase 2
35
Galunisertib + PlaceboEli LillyPhase 2/3
38
DSP-7888Sumitomo PharmaPhase 1/2
32
TP-0184Sumitomo PharmaPhase 1/2
24
DecitabineJohnson & JohnsonPhase 2
35
Epoetin alfaJohnson & JohnsonPhase 2
27
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
35